Insulin glargine: commentary on the duration of action and lower risk of nocturnal hypoglycaemia in patients with diabetes.
Rosenstock
Julio
J
Owens
David
D
D002940:Circadian Rhythm; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting
D003692:Delayed-Action Preparations; D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine